SCHEMBL5330184

SCHEMBL5330184

Nc1ccccc1-n1cnnn1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.58
NPSR1 Q6W5P4 1/20 0.58
NOTUM Q6P988 2/20 0.53
KMT2A Q03164 4/20 0.45
KDM4E B2RXH2 3/20 0.45
NPC1 O15118 1/20 0.42
GAA P10253 2/20 0.42
F2 P00734 1/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.40
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
TP53 P04637 1/20 0.39
HTT P42858 1/20 0.39
HSD17B10 Q99714 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30084182 1.00 ALDH1A1 (0.58) ALDH1A1NPSR1NOTUMKMT2AKDM4E
SCHEMBL12615992 0.85 ALDH1A1 (0.68) ALDH1A1NPSR1NOTUMKMT2AKDM4E
SCHEMBL11146019 0.85 ALDH1A1 (0.54) ALDH1A1NPSR1NOTUMKMT2AKDM4E
SCHEMBL8540440 0.76 ALDH1A1 (0.58) ALDH1A1NPSR1NOTUMKMT2AKDM4E
SCHEMBL5549180 0.76 ALDH1A1 (0.58) ALDH1A1NPSR1NOTUMKMT2AKDM4E
SCHEMBL436604 0.76 ALDH1A1 (0.58) ALDH1A1NPSR1NOTUMKMT2AKDM4E
SCHEMBL8109135 0.76 ALDH1A1 (0.58) ALDH1A1NPSR1NOTUMKMT2AKDM4E
SCHEMBL14242848 0.76 ALDH1A1 (0.58) ALDH1A1NPSR1NOTUMKMT2AKDM4E
SCHEMBL28955008 0.76 ALDH1A1 (0.58) ALDH1A1NPSR1NOTUMKMT2AKDM4E
SCHEMBL20237265 0.76 ALDH1A1 (0.58) ALDH1A1NPSR1NOTUMKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4514784-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE Petra Pharma Corporation (US) 2025-03-05 EP disclosed
US-11993729-B2 Chemical mechanical polishing composition BASF SE (DE) 2024-05-28 US disclosed
WO-2024026424-A1 QUINAZOLINONE DERIVATIVES AS AND RELATED USES BLACK DIAMOND THERAPEUTICS, INC. (US) 2024-02-01 WO disclosed
US-20240018115-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE LOXO ONCOLOGY, INC. 2024-01-18 US disclosed
WO-2023212693-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PETRA PHARMA CORPORATION (US) 2023-11-02 WO disclosed
EP-3714012-B1 CHEMICAL MECHANICAL POLISHING COMPOSITION BASF SE (DE) 2023-01-11 EP disclosed
US-20210102093-A1 USE OF A CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION FOR POLISHING OF COBALT COMPRISING SUBSTRATES BASF SE (DE) 2021-04-08 US disclosed
US-10899945-B2 Use of a chemical mechanical polishing (CMP) composition for polishing of cobalt comprising substrates BASF SE (DE) 2021-01-26 US disclosed
EP-3714012-A1 CHEMICAL MECHANICAL POLISHING COMPOSITION BASF SE (DE) 2020-09-30 EP disclosed
US-20200299547-A1 CHEMICAL MECHANICAL POLISHING COMPOSITION BASF SE (DE) 2020-09-24 US disclosed
EP-3334794-B1 USE OF A CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION FOR POLISHING OF COBALT COMPRISING SUBSTRATES BASF SE (DE) 2020-02-19 EP disclosed
WO-2019101555-A1 CHEMICAL MECHANICAL POLISHING COMPOSITION BASF SE (DE) 2019-05-31 WO disclosed
EP-3334794-A1 USE OF A CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION FOR POLISHING OF COBALT COMPRISING SUBSTRATES BASF SE (DE) 2018-06-20 EP disclosed
WO-2017025536-A1 USE OF A CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION FOR POLISHING OF COBALT COMPRISING SUBSTRATES BASF SE (DE) 2017-02-16 WO disclosed
WO-2007056215-A9 N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF CYTOVIA INC (US) 2007-09-13 WO disclosed
WO-2007056215-A2 N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF CYTOVIA, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018115-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PIK3CA, PIK3R4, PIK3R5 ALDH1A1 3412/4885NPSR1 2588/4885NOTUM 2689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.